484 articles in this topic
Retrospective study of 120 NSCLC patients finds thymalfasin plus chemoimmunotherapy significantly extends PFS and OS without added toxicity.
A next-gen RAS inhibitor called daraxonrasib targets KRAS-mutant cholangiocarcinoma, showing strong preclinical results and early clinical activity.
JYP0322 overcomes drug resistance and penetrates the brain, showing remarkable efficacy in heavily pretreated NSCLC patients.
A growth factor called GDF11 reprograms pro-tumor macrophages by rewiring their metabolism, suppressing hepatocellular carcinoma growth.
New 3-D spatial mapping reveals four distinct immune-evasion niches in osteosarcoma that explain why checkpoint therapies fail.
A large pooled study finds heavy drinking raises colorectal cancer risk across all molecular subtypes, suggesting a broad carcinogenic mechanism.
A blood-based immune biomarker predicts which breast cancer patients will respond to checkpoint immunotherapy, validated across two independent cohorts.
Researchers clarify how a clinical-radiological model can guide—and where it falls short—in managing hepatocellular carcinoma treated with TACE.
Novel payload technologies are reshaping antibody-drug conjugates, promising more precise and potent cancer therapies with fewer side effects.
Pyrroloquinoline quinone has demonstrated anticancer activity in preclinical studies, but human cancer trials remain absent. Here's where the science stands.
A tryptophan-derived gut metabolite suppresses colorectal cancer by blocking a key glycolysis enzyme via STAT3 inhibition.
PQQ, a widely available dietary supplement, inhibits EZH2 and suppresses B-cell lymphoma proliferation in lab studies.
